^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ABL1 T315I

    i
    Other names: ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
    Entrez ID:
    25
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (NCT04530565)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    01/25/2021
    Primary completion :
    07/01/2028
    Completion :
    07/01/2028
    ABL1 • BCR
    |
    ABL1 T315I
    |
    dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection
    Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older (NCT02494882)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    07/29/2024
    Initiation :
    06/29/2015
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP
    |
    BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R
    |
    dasatinib • Jakafi (ruxolitinib) • dexamethasone
    A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (NCT04501614)
    Phase 1/2
    Takeda
    Active, not recruiting
    Last update posted :
    03/04/2024
    Initiation :
    02/24/2021
    Primary completion :
    12/19/2024
    Completion :
    01/04/2027
    ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4
    |
    BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation
    |
    cytarabine • Iclusig (ponatinib) • cyclophosphamide
    Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses (OPTIC) (NCT02467270)
    Phase 2
    Takeda
    Active, not recruiting
    Last update posted :
    02/06/2024
    Initiation :
    06/30/2015
    Primary completion :
    04/14/2020
    Completion :
    06/01/2024
    ABL1 • BCR
    |
    BCR-ABL1 fusion • ABL1 T315I • BCR-ABL1 mutation
    |
    Iclusig (ponatinib)
    Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL (HQP1351CU101) (NCT04260022)
    Phase 1
    Ascentage Pharma Group Inc.
    Recruiting
    Last update posted :
    11/28/2023
    Initiation :
    01/09/2020
    Primary completion :
    01/31/2024
    Completion :
    01/31/2024
    ABL1 • BCR
    |
    ABL1 T315I
    |
    Blincyto (blinatumomab) • Nailike (olverembatinib)
    Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (AIM4CML) (NCT04666259)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    09/07/2023
    Initiation :
    05/25/2021
    Primary completion :
    06/20/2023
    Completion :
    07/05/2024
    ABL1 • BCR
    |
    ABL1 T315I • BCR-ABL1 mutation
    |
    Scemblix (asciminib)
    Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation (NCT05611216)
    Phase N/A
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    04/06/2023
    Initiation :
    12/01/2020
    Primary completion :
    12/23/2021
    Completion :
    12/23/2021
    ABL1 • BCR
    |
    ABL1 T315I
    A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation (NCT03883100)
    Phase 2
    Ascentage Pharma Group Inc.
    Active, not recruiting
    Last update posted :
    04/03/2023
    Initiation :
    04/08/2019
    Primary completion :
    04/01/2024
    Completion :
    03/01/2025
    ABL1 • BCR
    |
    ABL1 T315I
    |
    Nailike (olverembatinib)
    A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation (NCT03883087)
    Phase 2
    Ascentage Pharma Group Inc.
    Active, not recruiting
    Last update posted :
    04/03/2023
    Initiation :
    04/08/2019
    Primary completion :
    05/01/2024
    Completion :
    02/01/2025
    ABL1 • BCR
    |
    ABL1 T315I
    |
    Nailike (olverembatinib)
    Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL (NCT05495035)
    Phase 1
    Institute of Hematology & Blood Diseases Hospital
    Recruiting
    Last update posted :
    03/02/2023
    Initiation :
    09/01/2022
    Primary completion :
    08/31/2024
    Completion :
    12/01/2024
    ABL1 • BCR
    |
    BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation
    |
    dexamethasone • Nailike (olverembatinib) • lisaftoclax (APG-2575)
    French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients (NCT05619978)
    Phase N/A
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    11/17/2022
    Initiation :
    05/03/2021
    Primary completion :
    10/29/2021
    Completion :
    10/29/2021
    ABL1
    |
    ABL1 T315I